- HER2 positive breast cancer or gastric cancer that is resistant to standard therapy or
for which no standard therapy is available
- Performance status of 0 or 1
- Adequate bone marrow, kidney and liver function
- Known CNS disease including, but not limited to, metastases
- History of exposure to certain cumulative doses of anthracyclines
- Grade 3 or higher hypersensitivity reaction to prior receipt of any antibody therapy
- Active and clinically significant bacterial, fungal, or viral infection
- Abnormal cardiac function defined by a LVEF
- Patients with previous history or active interstitial lung disease or pulmonary
fibrosis, or a history of other clinically significant lung diseases